PortalPublikationenHighly efficient reprogramming to pluripotency and directed ...

Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

Standard

Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. / Warren, Luigi; Manos, Philip D; Ahfeldt, Tim; Loh, Yuin-Han; Li, Hu; Lau, Frank; Ebina, Wataru; Mandal, Pankaj K; Smith, Zachary D; Meissner, Alexander; Daley, George Q; Brack, Andrew S; Collins, James J; Cowan, Chad; Schlaeger, Thorsten M; Rossi, Derrick J.

in: CELL STEM CELL, Jahrgang 7, Nr. 5, 5, 2010, S. 618-630.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Warren, L, Manos, PD, Ahfeldt, T, Loh, Y-H, Li, H, Lau, F, Ebina, W, Mandal, PK, Smith, ZD, Meissner, A, Daley, GQ, Brack, AS, Collins, JJ, Cowan, C, Schlaeger, TM & Rossi, DJ 2010, 'Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.', CELL STEM CELL, Jg. 7, Nr. 5, 5, S. 618-630. <http://www.ncbi.nlm.nih.gov/pubmed/20888316?dopt=Citation>

APA

Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., Daley, G. Q., Brack, A. S., Collins, J. J., Cowan, C., Schlaeger, T. M., & Rossi, D. J. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. CELL STEM CELL, 7(5), 618-630. [5]. http://www.ncbi.nlm.nih.gov/pubmed/20888316?dopt=Citation

Vancouver

Warren L, Manos PD, Ahfeldt T, Loh Y-H, Li H, Lau F et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. CELL STEM CELL. 2010;7(5):618-630. 5.

Bibtex

@article{38c9c2c33d994136ae7d0e43424ef800,
title = "Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.",
abstract = "Clinical application of induced pluripotent stem cells (iPSCs) is limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically useful cell types are lacking. Here we describe a simple, nonintegrating strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate antiviral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem cells (RiPSCs) into terminally differentiated myogenic cells. This technology represents a safe, efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, and regenerative medicine.",
keywords = "Humans, Cells, Cultured, Cell Differentiation drug effects, Cell Lineage, Induced Pluripotent Stem Cells cytology, Nuclear Reprogramming genetics, RNA, Messenger pharmacology, Humans, Cells, Cultured, Cell Differentiation drug effects, Cell Lineage, Induced Pluripotent Stem Cells cytology, Nuclear Reprogramming genetics, RNA, Messenger pharmacology",
author = "Luigi Warren and Manos, {Philip D} and Tim Ahfeldt and Yuin-Han Loh and Hu Li and Frank Lau and Wataru Ebina and Mandal, {Pankaj K} and Smith, {Zachary D} and Alexander Meissner and Daley, {George Q} and Brack, {Andrew S} and Collins, {James J} and Chad Cowan and Schlaeger, {Thorsten M} and Rossi, {Derrick J}",
year = "2010",
language = "Deutsch",
volume = "7",
pages = "618--630",
journal = "CELL STEM CELL",
issn = "1934-5909",
publisher = "Cell Press",
number = "5",

}

RIS

TY - JOUR

T1 - Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA.

AU - Warren, Luigi

AU - Manos, Philip D

AU - Ahfeldt, Tim

AU - Loh, Yuin-Han

AU - Li, Hu

AU - Lau, Frank

AU - Ebina, Wataru

AU - Mandal, Pankaj K

AU - Smith, Zachary D

AU - Meissner, Alexander

AU - Daley, George Q

AU - Brack, Andrew S

AU - Collins, James J

AU - Cowan, Chad

AU - Schlaeger, Thorsten M

AU - Rossi, Derrick J

PY - 2010

Y1 - 2010

N2 - Clinical application of induced pluripotent stem cells (iPSCs) is limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically useful cell types are lacking. Here we describe a simple, nonintegrating strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate antiviral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem cells (RiPSCs) into terminally differentiated myogenic cells. This technology represents a safe, efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, and regenerative medicine.

AB - Clinical application of induced pluripotent stem cells (iPSCs) is limited by the low efficiency of iPSC derivation and the fact that most protocols modify the genome to effect cellular reprogramming. Moreover, safe and effective means of directing the fate of patient-specific iPSCs toward clinically useful cell types are lacking. Here we describe a simple, nonintegrating strategy for reprogramming cell fate based on administration of synthetic mRNA modified to overcome innate antiviral responses. We show that this approach can reprogram multiple human cell types to pluripotency with efficiencies that greatly surpass established protocols. We further show that the same technology can be used to efficiently direct the differentiation of RNA-induced pluripotent stem cells (RiPSCs) into terminally differentiated myogenic cells. This technology represents a safe, efficient strategy for somatic cell reprogramming and directing cell fate that has broad applicability for basic research, disease modeling, and regenerative medicine.

KW - Humans

KW - Cells, Cultured

KW - Cell Differentiation drug effects

KW - Cell Lineage

KW - Induced Pluripotent Stem Cells cytology

KW - Nuclear Reprogramming genetics

KW - RNA, Messenger pharmacology

KW - Humans

KW - Cells, Cultured

KW - Cell Differentiation drug effects

KW - Cell Lineage

KW - Induced Pluripotent Stem Cells cytology

KW - Nuclear Reprogramming genetics

KW - RNA, Messenger pharmacology

M3 - SCORING: Zeitschriftenaufsatz

VL - 7

SP - 618

EP - 630

JO - CELL STEM CELL

JF - CELL STEM CELL

SN - 1934-5909

IS - 5

M1 - 5

ER -